We are advancing clinical and preclinical therapeutic candidates to address significant unmet medical needs for patients suffering from severe neurological disorders.

Pipeline

Pipeline Consisting of First-in-Class Peptide Therapeutics Focused on Hard to Drug Targets in Neuroscience

Pipeline

  • Note:
  • Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Lobar Degeneration (FTLD), Facioscapulohumeral Muscular Dystrophy (FSHD) and Inclusion Body Myositis (IBM)
  • Interference peptides: block protein-protein interactions
  • Bi-functional Degraders: block the protein signalling pathway and degrade the disease causing protein